Growth hormone/IGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon β-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis
| Autor: | Claudia Pivonello, Francesco Saccà, Alessandra Cianflone, Antonio Carotenuto, C. Di Somma, F. Ausiello, A. Colao, Marcello Moccia, C. De Luca Picione, R Lanzillo, Camilla Russo, Angela Marsili, Giorgia Puorro, V. Brescia Morra, Mario Quarantelli |
|---|---|
| Přispěvatelé: | Lanzillo, Roberta, Di Somma, C, Quarantelli, M, Carotenuto, A, Pivonello, Claudia, Moccia, M, Cianflone, A, Marsili, A, Puorro, G, Sacca', Francesco, Russo, C. V, De Luca Picione, C, Ausiello, F, Colao, Annamaria, BRESCIA MORRA, Vincenzo |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Multiple Sclerosis Arginine interferon beta-1b medicine.medical_treatment 030209 endocrinology & metabolism Growth Hormone-Releasing Hormone Pathogenesis insulin-like growth factor 03 medical and health sciences Insulin-like growth factor 0302 clinical medicine Internal medicine medicine Humans Longitudinal Studies Insulin-Like Growth Factor I conversion Neurologic Examination Clinically isolated syndrome medicine.diagnostic_test business.industry Human Growth Hormone Multiple sclerosis Electrodiagnosis Interferon beta-1b Magnetic resonance imaging stimulation test medicine.disease Magnetic Resonance Imaging Endocrinology Treatment Outcome Neurology clinically isolated syndrome multiple sclerosi growth hormone Disease Progression Female Neurology (clinical) business 030217 neurology & neurosurgery Hormone Follow-Up Studies |
| Zdroj: | European journal of neurology 24 (2017): 446–449. doi:10.1111/ene.13207 info:cnr-pdr/source/autori:Lanzillo, R.; Di Somma, C.; Quarantelli, M.; Carotenuto, A.; Pivonello, C.; Moccia, M.; Cianflone, A.; Marsili, A.; Puorro, G.; Sacca, F.; Russo, C. V.; Picione, C. De Luca; Ausiello, F.; Colao, A.; Morra, V. Brescia/titolo:Growth hormone%2FIGF-1 axis longitudinal evaluation in clinically isolated syndrome patients on interferon-1b therapy: stimulation tests and correlations with clinical and radiological conversion to multiple sclerosis/doi:10.1111%2Fene.13207/rivista:European journal of neurology (Print)/anno:2017/pagina_da:446/pagina_a:449/intervallo_pagine:446–449/volume:24 |
| DOI: | 10.1111/ene.13207 |
| Popis: | BACKGROUND AND PURPOSE Growth hormone (GH)/insulin-like growth factor 1 (IGF-1) axis abnormalities in multiple sclerosis (MS) suggest their role in its pathogenesis. Interferon β (IFN-β) efficacy could be mediated also by an increase of IGF-1 levels. A 2-year longitudinal study was performed to estimate the prevalence of GH and/or IGF-1 deficiency in clinically isolated syndrome (CIS) patients and their correlation with conversion to MS in IFN treated patients. METHODS Clinical and demographic features of CIS patients were collected before the start of IFN-β-1b. IGF-1 levels and GH response after arginine and GH releasing hormone + arginine stimulation tests were assessed. Clinical and magnetic resonance imaging evaluations were performed at baseline, 1 year and 2 years. RESULTS Thirty CIS patients (24 female) were enrolled. At baseline, four patients (13%) showed a hypothalamic GH deficiency (GHD), whilst no one had a pituitary GHD. Baseline demographic, clinical and radiological data were not related to GHD, whilst IGF-1 levels were inversely related to age (P < 0.001) and GH levels (P = 0.03). GH and IGF-1 serum mean levels were not significantly modified after 1 and 2 years of treatment in the whole group, although 3/4 GHD patients experienced a normalization of GH levels, whilst one dropped out. After 2 years of treatment 13/28 (46%) patients converted to MS. The presence of GHD and GH and IGF-1 levels were not predictive of relapses, new T2 lesions or conversion occurrence. CONCLUSIONS Growth hormone/IGF-1 axis function was found to be frequently altered in CIS patients, but this was not related to MS conversion. Patients experienced an improvement of GHD during IFN therapy. Longer follow-up is necessary to assess its impact on disease progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|